Valuation Haemonetics Corporation
Stocks
HAE
US4050241003
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
07:00:03 31/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 119.65 USD | -0.12% |
|
+3.00% | +49.28% |
| 20/10 | Haemonetics Gets FDA Approval for Vascular Closure Device | DJ |
| 20/10 | Haemonetics says FDA clears vascular closure device | RE |
Company Valuation: Haemonetics Corporation
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,068 | 3,992 | 4,335 | 3,175 | 2,511 | 5,450 | - | - |
| Change | - | 30.13% | 8.58% | -26.76% | -20.89% | 117.02% | - | - |
| Enterprise Value (EV) 1 | 3,582 | 4,473 | 4,335 | 4,093 | 3,490 | 6,112 | 5,777 | 5,419 |
| Change | - | 24.89% | -3.1% | -5.58% | -14.71% | 75.11% | -5.48% | -6.2% |
| P/E | 71.5x | 35.3x | 37.3x | 19.1x | 26.4x | 30.2x | 26.5x | 23x |
| PBR | 4.09x | 4.88x | - | 3.71x | 3.21x | 5.12x | 3.99x | 3.22x |
| PEG | - | 0x | 16.71x | 0.4x | -0.7x | 0.3x | 1.9x | 1.5x |
| Capitalization / Revenue | 3.09x | 3.42x | 3.31x | 2.33x | 1.88x | 3.85x | 3.64x | 3.41x |
| EV / Revenue | 3.61x | 3.83x | 3.31x | 3.01x | 2.62x | 4.31x | 3.86x | 3.39x |
| EV / EBITDA | 12.6x | 14.7x | 11.7x | 9.67x | 7.93x | 13.5x | 11.7x | 10.5x |
| EV / EBIT | 19.1x | 20.5x | 15.7x | 12.5x | 10.3x | 16.6x | 14.5x | 12.3x |
| EV / FCF | - | - | 37.5x | 33.7x | 13.4x | 19.3x | 17.2x | 15.1x |
| FCF Yield | - | - | 2.66% | 2.96% | 7.46% | 5.19% | 5.8% | 6.61% |
| Dividend per Share 2 | - | - | - | - | - | 1 | - | - |
| Rate of return | - | - | - | - | - | 0.84% | - | - |
| EPS 2 | 0.84 | 2.24 | 2.29 | 3.31 | 2.05 | 3.963 | 4.507 | 5.21 |
| Distribution rate | - | - | - | - | - | 25.2% | - | - |
| Net sales 1 | 993.2 | 1,169 | 1,309 | 1,361 | 1,334 | 1,417 | 1,495 | 1,599 |
| EBITDA 1 | 284.9 | 304.7 | 370.1 | 423.3 | 440.1 | 452.5 | 491.8 | 516.1 |
| EBIT 1 | 187.1 | 218.4 | 276.5 | 326.3 | 338.5 | 368.2 | 399 | 440.2 |
| Net income 1 | 43.38 | 115.4 | 117.6 | 167.7 | 97.31 | 177.4 | 207.2 | 239.6 |
| Net Debt 1 | 514.1 | 481.4 | - | 918 | 979.1 | 662 | 327.1 | -31.34 |
| Reference price 2 | 60.02 | 79.13 | 85.35 | 63.19 | 54.04 | 119.65 | 119.65 | 119.65 |
| Nbr of stocks (in thousands) | 51,112 | 50,448 | 50,786 | 50,237 | 46,471 | 45,497 | - | - |
| Announcement Date | 10/5/22 | 11/5/23 | 9/5/24 | 8/5/25 | 7/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.22x | 4.31x | 13.51x | 0.83% | 5.45B | |
| 34.6x | 4.09x | 15.38x | 2.48% | 181B | |
| 24.27x | 4.74x | 16.63x | 1.15% | 120B | |
| 20.89x | 3.59x | 12.86x | 2.92% | 119B | |
| 31.27x | 3.02x | 12.17x | 2.28% | 91.44B | |
| 18.13x | 0.21x | 13.12x | 0.72% | 63.07B | |
| 31.81x | 7.93x | 20.4x | 1.24% | 55.8B | |
| 39.34x | 3.62x | 12.34x | 2.11% | 54.03B | |
| 39.01x | 9.68x | 27.09x | -.--% | 45.38B | |
| 44.15x | 3.33x | 12.39x | 0.52% | 34.37B | |
| Average | 31.37x | 4.45x | 15.59x | 1.43% | 76.89B | |
| Weighted average by Cap. | 29.91x | 4.21x | 15.31x | 1.81% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- HAE Stock
- Valuation Haemonetics Corporation
Select your edition
All financial news and data tailored to specific country editions
